The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Growth hormone deficiency (GHD) is a medical condition due to not enough growth hormone (GH). ... Some cases are associated with a lack of other pituitary hormones, in which case it is known as combined pituitary hormone deficiency. Diagnosis involves blood tests to measure growth hormone levels.
The global Growth Hormone Deficiency Therapy market was valued at US$ 4412 million in 2023 and is anticipated to reach US$ 6595.5 million by 2030, witnessing a CAGR of 5.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Growth Hormone Deficiency Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Growth Hormone Deficiency Therapy.
Report Scope
The Growth Hormone Deficiency Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Growth Hormone Deficiency Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Growth Hormone Deficiency Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
- Eli Lilly
- Pfizer
- AbbVie
- Novo Nordisk
- Merck KGaA
- Viatris
- Bayer
- Teva
- Novartis
- Abbott
- Roche
- Endo International
- Ipsen
- ANI Pharmaceuticals
- TherapeuticsMD
Segment by Type
- Parenteral
- Transdermal
- Oral
- Others
Segment by Application
- Hospitals
- Drugstores
- Others
By Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Netherlands)
- Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
- Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Growth Hormone Deficiency Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Growth Hormone Deficiency Therapy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Parenteral
1.2.3 Transdermal
1.2.4 Oral
1.2.5 Others
1.3 Market by Application
1.3.1 Global Growth Hormone Deficiency Therapy Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Growth Hormone Deficiency Therapy Market Perspective (2019-2030)
2.2 Growth Hormone Deficiency Therapy Growth Trends by Region
2.2.1 Global Growth Hormone Deficiency Therapy Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Growth Hormone Deficiency Therapy Historic Market Size by Region (2019-2024)
2.2.3 Growth Hormone Deficiency Therapy Forecasted Market Size by Region (2025-2030)
2.3 Growth Hormone Deficiency Therapy Market Dynamics
2.3.1 Growth Hormone Deficiency Therapy Industry Trends
2.3.2 Growth Hormone Deficiency Therapy Market Drivers
2.3.3 Growth Hormone Deficiency Therapy Market Challenges
2.3.4 Growth Hormone Deficiency Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Growth Hormone Deficiency Therapy Players by Revenue
3.1.1 Global Top Growth Hormone Deficiency Therapy Players by Revenue (2019-2024)
3.1.2 Global Growth Hormone Deficiency Therapy Revenue Market Share by Players (2019-2024)
3.2 Global Growth Hormone Deficiency Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Growth Hormone Deficiency Therapy Revenue
3.4 Global Growth Hormone Deficiency Therapy Market Concentration Ratio
3.4.1 Global Growth Hormone Deficiency Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Growth Hormone Deficiency Therapy Revenue in 2023
3.5 Growth Hormone Deficiency Therapy Key Players Head office and Area Served
3.6 Key Players Growth Hormone Deficiency Therapy Product Solution and Service
3.7 Date of Enter into Growth Hormone Deficiency Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Growth Hormone Deficiency Therapy Breakdown Data by Type
4.1 Global Growth Hormone Deficiency Therapy Historic Market Size by Type (2019-2024)
4.2 Global Growth Hormone Deficiency Therapy Forecasted Market Size by Type (2025-2030)
5 Growth Hormone Deficiency Therapy Breakdown Data by Application
5.1 Global Growth Hormone Deficiency Therapy Historic Market Size by Application (2019-2024)
5.2 Global Growth Hormone Deficiency Therapy Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Growth Hormone Deficiency Therapy Market Size (2019-2030)
6.2 North America Growth Hormone Deficiency Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Growth Hormone Deficiency Therapy Market Size by Country (2019-2024)
6.4 North America Growth Hormone Deficiency Therapy Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Growth Hormone Deficiency Therapy Market Size (2019-2030)
7.2 Europe Growth Hormone Deficiency Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Growth Hormone Deficiency Therapy Market Size by Country (2019-2024)
7.4 Europe Growth Hormone Deficiency Therapy Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Growth Hormone Deficiency Therapy Market Size (2019-2030)
8.2 Asia-Pacific Growth Hormone Deficiency Therapy Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Growth Hormone Deficiency Therapy Market Size by Region (2019-2024)
8.4 Asia-Pacific Growth Hormone Deficiency Therapy Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Growth Hormone Deficiency Therapy Market Size (2019-2030)
9.2 Latin America Growth Hormone Deficiency Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Growth Hormone Deficiency Therapy Market Size by Country (2019-2024)
9.4 Latin America Growth Hormone Deficiency Therapy Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Growth Hormone Deficiency Therapy Market Size (2019-2030)
10.2 Middle East & Africa Growth Hormone Deficiency Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Growth Hormone Deficiency Therapy Market Size by Country (2019-2024)
10.4 Middle East & Africa Growth Hormone Deficiency Therapy Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Company Detail
11.1.2 Eli Lilly Business Overview
11.1.3 Eli Lilly Growth Hormone Deficiency Therapy Introduction
11.1.4 Eli Lilly Revenue in Growth Hormone Deficiency Therapy Business (2019-2024)
11.1.5 Eli Lilly Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Growth Hormone Deficiency Therapy Introduction
11.2.4 Pfizer Revenue in Growth Hormone Deficiency Therapy Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Detail
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Growth Hormone Deficiency Therapy Introduction
11.3.4 AbbVie Revenue in Growth Hormone Deficiency Therapy Business (2019-2024)
11.3.5 AbbVie Recent Development
11.4 Novo Nordisk
11.4.1 Novo Nordisk Company Detail
11.4.2 Novo Nordisk Business Overview
11.4.3 Novo Nordisk Growth Hormone Deficiency Therapy Introduction
11.4.4 Novo Nordisk Revenue in Growth Hormone Deficiency Therapy Business (2019-2024)
11.4.5 Novo Nordisk Recent Development
11.5 Merck KGaA
11.5.1 Merck KGaA Company Detail
11.5.2 Merck KGaA Business Overview
11.5.3 Merck KGaA Growth Hormone Deficiency Therapy Introduction
11.5.4 Merck KGaA Revenue in Growth Hormone Deficiency Therapy Business (2019-2024)
11.5.5 Merck KGaA Recent Development
11.6 Viatris
11.6.1 Viatris Company Detail
11.6.2 Viatris Business Overview
11.6.3 Viatris Growth Hormone Deficiency Therapy Introduction
11.6.4 Viatris Revenue in Growth Hormone Deficiency Therapy Business (2019-2024)
11.6.5 Viatris Recent Development
11.7 Bayer
11.7.1 Bayer Company Detail
11.7.2 Bayer Business Overview
11.7.3 Bayer Growth Hormone Deficiency Therapy Introduction
11.7.4 Bayer Revenue in Growth Hormone Deficiency Therapy Business (2019-2024)
11.7.5 Bayer Recent Development
11.8 Teva
11.8.1 Teva Company Detail
11.8.2 Teva Business Overview
11.8.3 Teva Growth Hormone Deficiency Therapy Introduction
11.8.4 Teva Revenue in Growth Hormone Deficiency Therapy Business (2019-2024)
11.8.5 Teva Recent Development
11.9 Novartis
11.9.1 Novartis Company Detail
11.9.2 Novartis Business Overview
11.9.3 Novartis Growth Hormone Deficiency Therapy Introduction
11.9.4 Novartis Revenue in Growth Hormone Deficiency Therapy Business (2019-2024)
11.9.5 Novartis Recent Development
11.10 Abbott
11.10.1 Abbott Company Detail
11.10.2 Abbott Business Overview
11.10.3 Abbott Growth Hormone Deficiency Therapy Introduction
11.10.4 Abbott Revenue in Growth Hormone Deficiency Therapy Business (2019-2024)
11.10.5 Abbott Recent Development
11.11 Roche
11.11.1 Roche Company Detail
11.11.2 Roche Business Overview
11.11.3 Roche Growth Hormone Deficiency Therapy Introduction
11.11.4 Roche Revenue in Growth Hormone Deficiency Therapy Business (2019-2024)
11.11.5 Roche Recent Development
11.12 Endo International
11.12.1 Endo International Company Detail
11.12.2 Endo International Business Overview
11.12.3 Endo International Growth Hormone Deficiency Therapy Introduction
11.12.4 Endo International Revenue in Growth Hormone Deficiency Therapy Business (2019-2024)
11.12.5 Endo International Recent Development
11.13 Ipsen
11.13.1 Ipsen Company Detail
11.13.2 Ipsen Business Overview
11.13.3 Ipsen Growth Hormone Deficiency Therapy Introduction
11.13.4 Ipsen Revenue in Growth Hormone Deficiency Therapy Business (2019-2024)
11.13.5 Ipsen Recent Development
11.14 ANI Pharmaceuticals
11.14.1 ANI Pharmaceuticals Company Detail
11.14.2 ANI Pharmaceuticals Business Overview
11.14.3 ANI Pharmaceuticals Growth Hormone Deficiency Therapy Introduction
11.14.4 ANI Pharmaceuticals Revenue in Growth Hormone Deficiency Therapy Business (2019-2024)
11.14.5 ANI Pharmaceuticals Recent Development
11.15 TherapeuticsMD
11.15.1 TherapeuticsMD Company Detail
11.15.2 TherapeuticsMD Business Overview
11.15.3 TherapeuticsMD Growth Hormone Deficiency Therapy Introduction
11.15.4 TherapeuticsMD Revenue in Growth Hormone Deficiency Therapy Business (2019-2024)
11.15.5 TherapeuticsMD Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
